Pfizer to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.
Budget with ET
Sitharaman likely to give India’s ‘Aam Aadmi’ what they want in Budget?
Can Budget 2025 address India's unemployment woes?
Can the Budget provide a delta to the China plus one effort?
The sale represents nearly 7.7% of issued share capital of Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019. It was spun off from the British drugmaker in 2022.
Pfizer, which will remain the largest shareholder in Haleon after the sale, had in 2023 said it would cut its ownership in a 'slow and methodical' manner within months.
The U.S. drugmaker is under pressure from hedge fund Starboard Value to hold its management accountable for underperformance. Last October, it sold a $3.3 billion stake in the maker of Sensodyne, while GSK sold its entire stake in May.
J.P. Morgan and Morgan Stanley are joint global coordinators and joint bookrunners for the share sale.
Artificial Intelligence(AI)
Java Programming with ChatGPT: Learn using Generative AI
By — Metla Sudha Sekhar, IT Specialist and Developer
Artificial Intelligence(AI)
Basics of Generative AI: Unveiling Tomorrows Innovations
By — Metla Sudha Sekhar, IT Specialist and Developer
Artificial Intelligence(AI)
Generative AI for Dynamic Java Web Applications with ChatGPT
By — Metla Sudha Sekhar, IT Specialist and Developer
Artifi
